Physician profile
Bradley J Olsen
NPI 1750927927
$1,619.26
in general payments reported to CMS, 2019-2025
28 companies · $172 in 2025
The $172 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $211 · 2022: $571 · 2023: $336 · 2024: $330 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $837.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $633.99 | 2021-2025 | |
| Amgen INC. | $169.44 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $99.76 | 2022-2023 | |
| Pfizer INC. | $81.42 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.82 | 2021-2024 | Tradjenta, Jardiance, Synjardy |
| Novo Nordisk INC | $72.93 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $45.88 | 2023-2024 | Spravato |
| Lucid Diagnostics INC. | $37.78 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $37.53 | 2023 | Flumist Quadrivalent, Evusheld |
| Merck Sharp & Dohme LLC | $34.77 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.46 | 2022 | |
| Sumitomo Pharma America, INC. | $23.69 | 2024 | Gemtesa |
| Inogen, INC. | $22.42 | 2024 | |
| Nevro Corp. | $22.38 | 2022 | |
| Sanofi-Aventis U.S. LLC | $22.18 | 2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $19.44 | 2023 | |
| Neurocrine Biosciences, INC. | $19.28 | 2024 | Ingrezza |
| Kaleo, INC. | $18.61 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $18.05 | 2022 | |
| Lilly USA, LLC | $17.70 | 2024 | Mounjaro, Zepbound |
| Amarin Pharma, INC. | $16.45 | 2021 | |
| Becton, Dickinson and Company | $15.88 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $14.92 | 2022 | |
| Antares Pharma, INC. | $13.87 | 2024 | Xyosted |
| Glaxosmithkline, LLC. | $13.53 | 2023 | Shingrix |
| Organon LLC | $13.40 | 2023 | Nexplanon |
| Phathom Pharmaceuticals, INC. | $13.37 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $13.31 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Olsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.